230 related articles for article (PubMed ID: 31320349)
1. Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol.
Gonçalves CA; Lopes-Júnior LC; Nampo FK; Zilly A; Mayer PCM; Pereira-da-Silva G
BMJ Open; 2019 Jul; 9(7):e026975. PubMed ID: 31320349
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L; Hopkins L; Hutton B; Fergusson D
CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
[TBL] [Abstract][Full Text] [Related]
5. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis.
Kechagias KS; Kalliala I; Bowden SJ; Athanasiou A; Paraskevaidi M; Paraskevaidis E; Dillner J; Nieminen P; Strander B; Sasieni P; Veroniki AA; Kyrgiou M
BMJ; 2022 Aug; 378():e070135. PubMed ID: 35922074
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials.
Ibrahim Khalil A; Zhang L; Muwonge R; Sauvaget C; Basu P
BMJ Open; 2023 Oct; 13(10):e069616. PubMed ID: 37879679
[TBL] [Abstract][Full Text] [Related]
7. Human Papillomavirus Genotyping Compared With a Qualitative High-Risk Human Papillomavirus Test After Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Systematic Review.
Bottari F; Iacobone AD; Passerini R; Preti EP; Sandri MT; Cocuzza CE; Gary DS; Andrews JC
Obstet Gynecol; 2019 Sep; 134(3):452-462. PubMed ID: 31403602
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial.
van de Laar RLO; Hofhuis W; Duijnhoven RG; Polinder S; Melchers WJG; van Kemenade FJ; Bekkers RLM; Van Beekhuizen HJ
BMC Cancer; 2020 Jun; 20(1):539. PubMed ID: 32517663
[TBL] [Abstract][Full Text] [Related]
9. National genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: a systematic review and meta-analysis protocol.
Palmer M; Katanoda K; Saito E; Martellucci CA; Ostuki S; Nomura S; Ota E; Brotherton JML; Hocking J
Syst Rev; 2021 May; 10(1):135. PubMed ID: 33952342
[TBL] [Abstract][Full Text] [Related]
10. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia.
Barra F; Della Corte L; Noberasco G; Foreste V; Riemma G; Di Filippo C; Bifulco G; Orsi A; Icardi G; Ferrero S
J Obstet Gynaecol Res; 2020 Jul; 46(7):989-1006. PubMed ID: 32390320
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus immunogen that provides protective tumor immunity and induces tumor regression.
Marquez JP; Rivera R; Kang KH; Gardner MB; Torres JV
Viral Immunol; 2012 Apr; 25(2):141-52. PubMed ID: 22486305
[TBL] [Abstract][Full Text] [Related]
12. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test.
van der Heijden E; Lopes AD; Bryant A; Bekkers R; Galaal K
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010757. PubMed ID: 25562623
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
14. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
15. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and complication rates after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE Group.
Athanasiou A; Veroniki AA; Efthimiou O; Kalliala I; Naci H; Bowden S; Paraskevaidi M; Martin-Hirsch P; Bennett P; Paraskevaidis E; Salanti G; Kyrgiou M
BMJ Open; 2019 Aug; 9(8):e028008. PubMed ID: 31377697
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta-analysis.
Eriksen DO; Jensen PT; Schroll JB; Hammer A
Acta Obstet Gynecol Scand; 2022 Jun; 101(6):597-607. PubMed ID: 35470865
[TBL] [Abstract][Full Text] [Related]
18. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
Harper DM; Franco EL; Wheeler CM; Moscicki AB; Romanowski B; Roteli-Martins CM; Jenkins D; Schuind A; Costa Clemens SA; Dubin G;
Lancet; 2006 Apr; 367(9518):1247-55. PubMed ID: 16631880
[TBL] [Abstract][Full Text] [Related]
19. Protocol for a systematic review and meta-analysis of the diagnostic test accuracy of host and HPV DNA methylation in cervical cancer screening and management.
Bowden SJ; Ellis LB; Kalliala I; Paraskevaidi M; Tighe J; Kechagias KS; Doulgeraki T; Paraskevaidis E; Arbyn M; Flanagan J; Veroniki A; Kyrgiou M
BMJ Open; 2023 Jun; 13(6):e071534. PubMed ID: 37277222
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.
Harper DM; Nieminen P; Donders G; Einstein MH; Garcia F; Huh WK; Stoler MH; Glavini K; Attley G; Limacher JM; Bastien B; Calleja E
Gynecol Oncol; 2019 Jun; 153(3):521-529. PubMed ID: 30955915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
